NCAM1 and carcinoma: CD56 protein expression was seen 32/51 of benign lesions (73.7% HNs, and 30.8% FA), in 2/12 (16.7 %) NIFTP and in 12/20 carcinomas (52.9%FVPTC and 100%FC).CD56 was absent in 19/51 cases of benign lesions (26.3% of HNs and 69.2% of FA), in 10/12 (83.3%) NIFTP, and in 8/17 (47.1%) FVPC and in 0/3 (0%) FC.CD56 protein expression was significantly more common in benign FPTLs (HNs, and FA) as compared to malignant FPTLs (FVPTC and FC) and NIFTP (P value 0.003).A summary of these findings is shown in Tables 3 and 4.